136 INFLUDENCE OF RACE AND COMORBIDITY ON THERAPY FOR PROSTATE CANCER: EVOLUTION OVER 15 YEARS
Amee Morgans(Nashville Oncology Associates), David F. Penson(Geriatric Research Education and Clinical Center), Vivien W. Chen(Louisiana State University Health Sciences Center New Orleans), Sherrie H. Kaplan(University of California, Irvine), Daniel A. Barocas(Vanderbilt University Medical Center), Sheldon Greenfield(University of California, Irvine), Tatsuki Koyoma(Vanderbilt University Medical Center), Xiao‐Cheng Wu(London School of Hygiene & Tropical Medicine), Ann S. Hamilton(University of Southern California), Karen E. Hoffman(The University of Texas MD Anderson Cancer Center), Kang-Hsien Fan, Richard M. Hoffman(University of Iowa), Matthew J. Resnick(Vanderbilt University Medical Center), Antoinette Stroop
Cited by 0
Related Papers
Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2019|1.6k
Long-Term Functional Outcomes after Treatment for Localized Prostate Cancer
|New England Journal of Medicine|2013|975
Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomised, phase 3, non-inferiority trial
|The Lancet|2018|779
Gender and Bladder Cancer: A Collaborative Review of Etiology, Biology, and Outcomes
|European Urology|2015|688
Prostate Cancer, Version 1.2016
|Journal of the National Comprehensive Cancer Network|2016|656